BioCryst Pharmaceuticals (BCRX) News Today $10.79 +0.20 (+1.89%) Closing price 04:00 PM EasternExtended Trading$10.70 -0.09 (-0.84%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period BioCryst to Present at Upcoming Investor ConferencesMay 27 at 7:00 AM | globenewswire.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Reduced by Voloridge Investment Management LLCVoloridge Investment Management LLC trimmed its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 11.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,579,960 shares of the biotechnology comMay 27 at 4:46 AM | marketbeat.comWoodline Partners LP Makes New $3.39 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Woodline Partners LP acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 450,199 shares of the biotechnology company's stock, valued at approximately $3,385,000. WoodlineMay 27 at 4:37 AM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plcMan Group plc increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,954 shares of the biotechnology company's stockMay 27 at 3:53 AM | marketbeat.comNuveen Asset Management LLC Sells 1,395,503 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Nuveen Asset Management LLC lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 29.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,419,046 shares of the biotMay 25 at 3:48 AM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Raised by Two Sigma Advisers LPTwo Sigma Advisers LP boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,499,812 shares of the biotechnology company's stoMay 24 at 4:52 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded by StockNews.com to Strong-Buy RatingStockNews.com raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday.May 24 at 1:30 AM | marketbeat.comRafferty Asset Management LLC Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Rafferty Asset Management LLC trimmed its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 36.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 234,836 shares of the biotechnology comMay 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)D. E. Shaw & Co. Inc. raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 37.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 315,263 shares of the biotechnology companMay 23, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Boosted by Lazard Asset Management LLCLazard Asset Management LLC increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 68.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,516 shares of the biotechnologMay 22, 2025 | marketbeat.comDeutsche Bank AG Purchases 58,687 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Deutsche Bank AG boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 519,217 shares of the biotechnology companMay 22, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by StockNews.comMay 22, 2025 | americanbankingnews.comBNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)BNP Paribas Financial Markets lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 60.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 196,225 shares of the biotechnology company's stock after selling 300May 21, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Ameriprise Financial Inc. decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,720,581 shares of the biotechnology company's stock after selling 5May 21, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 119,719 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Jacobs Levy Equity Management Inc. lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 32.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 247,795 shares of the biotechnology company's stockMay 18, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Northern Trust CorpNorthern Trust Corp boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,004,911 shares of the biotechnology company's stMay 18, 2025 | marketbeat.comGraham Capital Management L.P. Invests $731,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Graham Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 97,257 shares of the biotechnology company's stock, valuMay 17, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Sells 195,621 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)The Manufacturers Life Insurance Company decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 65.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 103,531 shares of the biotechnology company'sMay 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Sells 247,167 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Parkman Healthcare Partners LLC cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 53.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 216,881 shares of the biotechnoMay 16, 2025 | marketbeat.comBioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)May 16, 2025 | globenewswire.comBioCryst's Orladeyo up for FDA review in pediatric HAE patientsMay 14, 2025 | msn.comBioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 YearsMay 14, 2025 | globenewswire.comBalyasny Asset Management L.P. Purchases Shares of 529,653 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Balyasny Asset Management L.P. acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 529,653 shares of the biotechnology company's stock, valued at approximately $3,983May 13, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Cuts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Price T Rowe Associates Inc. MD cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 94.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 126,806 shares of the biotechnology company'sMay 13, 2025 | marketbeat.comBayesian Capital Management LP Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Bayesian Capital Management LP bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,700 shares of the biotechnology coMay 11, 2025 | marketbeat.comBCRX FY2025 EPS Forecast Lifted by Cantor FitzgeraldBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for BioCryst Pharmaceuticals in a report released on Tuesday, May 6th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnoloMay 10, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of BCRX Q2 EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - HC Wainwright increased their Q2 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a research note issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.10 per shareMay 10, 2025 | marketbeat.comWedbush Issues Positive Estimate for BCRX EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Wedbush raised their Q2 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a note issued to investors on Monday, May 5th. Wedbush analyst L. Chico now anticipates that the bioMay 10, 2025 | marketbeat.comAQR Capital Management LLC Buys 52,047 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)AQR Capital Management LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 839,274 shares of the biotechnology company's stock after purchasing anMay 10, 2025 | marketbeat.comTudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology companMay 10, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $11.00Barclays boosted their target price on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday.May 9, 2025 | marketbeat.comHC Wainwright Has Positive Outlook for BCRX FY2029 EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright boosted their FY2029 earnings per share estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology compMay 9, 2025 | marketbeat.comResearch Analysts Set Expectations for BCRX Q3 EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at Wedbush boosted their Q3 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a report released on Monday, May 5th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earningsMay 9, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Grows Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Schonfeld Strategic Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 27.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 217,740 shares of the biMay 9, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Earns "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday.May 8, 2025 | marketbeat.comAnalysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest ResultsMay 8, 2025 | finance.yahoo.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $13.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday.May 8, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLCNeedham & Company LLC boosted their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday.May 8, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday.May 8, 2025 | marketbeat.comAlgert Global LLC Purchases 209,096 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Algert Global LLC boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 40.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 725,305 shares of the biotechnology company's stock aMay 8, 2025 | marketbeat.comFreestone Grove Partners LP Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Freestone Grove Partners LP purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 30,313 shares of the biotechnology company's stock, valuMay 8, 2025 | marketbeat.comHsbc Holdings PLC Has $677,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Hsbc Holdings PLC boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 33.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,061 shares of the biotechnologyMay 8, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 1-Year High After Earnings BeatBioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year High Following Earnings BeatMay 8, 2025 | marketbeat.comBioCryst Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders bought 2,675 call options on the stock. This is an increase of 174% compared to the average volume of 975 call options.May 7, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up Following Earnings BeatBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected EarningsMay 7, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Estimates By $0.27 EPSBioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.27. The business's revenue for the quarter was up 56.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS.May 7, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | insidermonkey.comBioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s PleasedMay 6, 2025 | msn.comWhy BioCryst Pharmaceuticals, Inc. (BCRX) Soared on MondayMay 6, 2025 | msn.comBioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...May 6, 2025 | gurufocus.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼1.361.02▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼156▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HALO News Today RGEN News Today MDGL News Today IONS News Today ALKS News Today LGND News Today FOLD News Today CLDX News Today MNKD News Today INVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCRX Stock Free BCRX Stock Alerts